"You can stop taking anti-inflammatory drugs when you start injection treatment for inflammatory bowel disease "
Aug 15, 2024
'Inflammatory bowel disease' In the treatment of patients, 5-ASA drugs (mesalamine), which are anti-inflammatory drugs, are primarily prescribed, and immunosuppressants may be used if the inflammation is severe.
This condition refers to the damage to the intestinal tract due to chronic and recurrent inflammation of the intestine, such as ulcerative colitis and Crohn's disease.
When existing drugs do not work, biological agents such as anti-TNF drugs, which are injections, are used by raising the drug to a higher level.
It is known that patients with "inflammatory bowel disease" should take drugs for life and should not stop treatment because recurrence occurs frequently if symptoms improve while using these drugs.
However, recently, when anti-TNF drugs that show excellent therapeutic effects on patients with 'inflammatory bowel disease' are used, research results have been published that it is possible to stop treating 5-ASA drugs, which are existing inflammatory bowel disease treatments.
Seo Jeong-guk, a professor of gastroenterology at Chung-Ang University Hospital, and a research team at Asan Medical Center in Seoul (Professor Ye Byung-deok, Dr. Kim Sun-ok) recently published a research paper comparing the prognosis of continuing or stopping 5-ASA drugs in patients with inflammatory bowel disease using anti-TNF drugs.
Professor Seo Jeong-guk's team analyzed whether there is a difference in prognosis between stopping and continuing treatment of 5-ASA drugs, which are previously used, when using anti-TNF drugs that show excellent effects on patients with inflammatory bowel disease based on big data from the Health Insurance Review and Assessment Service.
In a follow-up of 7442 'inflammatory bowel disease' patients for approximately 4.3 years, a total of 1037 (13.9%) stopped taking 5-ASA after the start of taking anti-TNF drugs, and compared to the persistent group, 5-ASA discontinuation was not associated with the occurrence of negative events such as hospitalization, surgery, or steroid use (adjusted risk ratio 1.01, 95% confidence interval 0.93 to 1.10).
Additional studies also confirmed that there was no difference in the occurrence of negative events depending on whether 5-ASA continued even when analyzed by dividing into Crohn's disease and ulcerative colitis patients.
In addition, there was no significant difference in the risk of negative events between the 5-ASA continuing group and the discontinued group in the subgroup analysis according to various risk factors such as age, gender, and chronic disease.
Professor Seo Jeong-guk "Until now, in the treatment of patients with inflammatory bowel disease, there has been insufficient evidence on whether 5-ASA drugs can be discontinued since injection began."This study confirmed that there was no difference in prognosis between continuing and stopping 5-ASA drug administration under these conditions, which gave patients the advantage of avoiding unnecessary drug use."
Meanwhile, the research team's research paper was published in the latest issue of the SCIE-level journal, the international top journal of gastrointestinal and pharmacology, 'Alimental Pharmacology & Therapeutics (204 IF 7.633)'.
This condition refers to the damage to the intestinal tract due to chronic and recurrent inflammation of the intestine, such as ulcerative colitis and Crohn's disease.
When existing drugs do not work, biological agents such as anti-TNF drugs, which are injections, are used by raising the drug to a higher level.
It is known that patients with "inflammatory bowel disease" should take drugs for life and should not stop treatment because recurrence occurs frequently if symptoms improve while using these drugs.
However, recently, when anti-TNF drugs that show excellent therapeutic effects on patients with 'inflammatory bowel disease' are used, research results have been published that it is possible to stop treating 5-ASA drugs, which are existing inflammatory bowel disease treatments.
Seo Jeong-guk, a professor of gastroenterology at Chung-Ang University Hospital, and a research team at Asan Medical Center in Seoul (Professor Ye Byung-deok, Dr. Kim Sun-ok) recently published a research paper comparing the prognosis of continuing or stopping 5-ASA drugs in patients with inflammatory bowel disease using anti-TNF drugs.
Professor Seo Jeong-guk's team analyzed whether there is a difference in prognosis between stopping and continuing treatment of 5-ASA drugs, which are previously used, when using anti-TNF drugs that show excellent effects on patients with inflammatory bowel disease based on big data from the Health Insurance Review and Assessment Service.
In a follow-up of 7442 'inflammatory bowel disease' patients for approximately 4.3 years, a total of 1037 (13.9%) stopped taking 5-ASA after the start of taking anti-TNF drugs, and compared to the persistent group, 5-ASA discontinuation was not associated with the occurrence of negative events such as hospitalization, surgery, or steroid use (adjusted risk ratio 1.01, 95% confidence interval 0.93 to 1.10).
Additional studies also confirmed that there was no difference in the occurrence of negative events depending on whether 5-ASA continued even when analyzed by dividing into Crohn's disease and ulcerative colitis patients.
In addition, there was no significant difference in the risk of negative events between the 5-ASA continuing group and the discontinued group in the subgroup analysis according to various risk factors such as age, gender, and chronic disease.
Professor Seo Jeong-guk "Until now, in the treatment of patients with inflammatory bowel disease, there has been insufficient evidence on whether 5-ASA drugs can be discontinued since injection began."This study confirmed that there was no difference in prognosis between continuing and stopping 5-ASA drug administration under these conditions, which gave patients the advantage of avoiding unnecessary drug use."
Meanwhile, the research team's research paper was published in the latest issue of the SCIE-level journal, the international top journal of gastrointestinal and pharmacology, 'Alimental Pharmacology & Therapeutics (204 IF 7.633)'.
|
bellho@sportschosun.com
